Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Acute myeloid leukemia (AML) with MLL partial tandem duplication (MLL-PTD) often presents a poor prognosis.
• Understanding the mutational landscape and order of acquisition is crucial for targeted therapies in MLL-PTD AML.

Purpose of the Study:

• To determine the sequence of MLL-PTD in relation to other common AML mutations.
• To identify novel mutations associated with the MLL-PTD AML subtype.

Main Methods:

• Whole exome and targeted sequencing were performed on 85 MLL-PTD AML patient samples.
• HiSeq-2000 sequencing technology was utilized.
• Clonality analysis was employed to infer mutation timing.

Main Results:

• Recurrent mutations were identified in cohesin complex gene STAG2, splicing factor U2AF1, and MGA.
• NPM1, a frequent AML mutation, was notably absent in MLL-PTD samples.
• Early clonal mutations include IDH2/1, DNMT3A, U2AF1, and TET2, preceding MLL-PTD.
• Later, largely subclonal mutations include FLT3 and RAS, associated with proliferation.

Conclusions:

• The study elucidates the mutational hierarchy in MLL-PTD AML, distinguishing early clonal events from later subclonal acquisitions.
• Identified mutations in STAG2, U2AF1, and MGA offer potential therapeutic targets.
• Findings provide critical insights for developing targeted treatment strategies for MLL-PTD AML.